Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer

Urology

Volumn 48, Issue 6, 1996, Pages 882-888

  Björk, Thomas ^a   Piironen, Timo ^b   Pettersson, Kim ^b   Lövgren, Timo ^b   Stenman, Ulf Håkan ^b   Oesterling, Joseph E ^b   Abrahamsson, Per Anders ^b   Lilja, Hans ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; DIAGNOSTIC VALUE; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; STATISTICAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 0030469505     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00486-4     Document Type: Article

References (19)

1. Oesterling JE: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907-923, 1991.
2. Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, and Cooner WH: Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 147: 815-816, 1992.
3. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, and Walsh PC: Longitudinal evaluation of prostate-specific levels in men with and without prostate disease. JAMA 267: 2215-2220, 1992.
4. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, and Lieber MM: Serum prostate specific antigen in a community-based population of healthy men. JAMA 270: 860-864, 1993.
5. Christensson A, Laurell C-B, and Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine protease inhibitors. Eur J Biochem 194: 755-763, 1990.
6. Stenman U-H, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, and Alfthan O: A complex between prostate-specific antigen and alpha-1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostate cancer. Cancer Res 51: 222-226, 1991.
7. Lilja H, Christensson A, Dahlén U, Matikainen MJ, Nilsson O, Pettersson K, and Lövgren T: Prostate specific antigen in serum occurs predominantly in complex with alpha-1-antichymotrypsin. Clin Chem 37: 1618-1625, 1991.
8. 1-antichymotrypsin as an indicator of prostate cancer. J Urol 150: 100-105, 1993.
9. Pettersson K, Piironen T, Seppälä M, Liukkonen L, Christensson A, Matikainen MJ, Suonpää M, Lövgren T, and Lilja H: Free and complexed prostate-specific antigen (PSA): in vitro stability, epitope map and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-alpha-1-antichymotrypsin complex. Clin Chem 41: 1480-1488, 1995.
10. Mitrunen K, Pettersson K, Piironen T, Björk T, Lilja H, and Lövgren T: Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem 41: 1115-1120, 1995.
11. Lövgren J, Piironen T, Övermo C, Dowell B, Karp M, Pettersson K, Lilja H, and Lundwall Å: Production of recombinant PSA and hK 2 and analysis of their immunologic cross-reactivity. Biochem Biophys Res Commun 213: 888-895, 1995.
12. Jacobsen S, Lilja H, Klee G, Wright GL, Pettersson K, and Oesterling JE: Comparability of the tandem-R and Imx assays for the measurement of serum prostate-specific antigen. Urology 44: 512-518, 1994.
13. Leinonen J, Lövgren T, Vornanen T, and Stenman U-H: Double-label time-resolved immunofluorometric assay of prostate-specific antigen and the complex between prostate-specific antigen with alpha-1-antichymotrypsin. Clin Chem 39: 2098-2103, 1993.
14. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, and Nadler RB: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274: 1214-1220, 1995.
15. Luderer AA, Chen Y-A, Soriano TF, Kramp WJ, Carlson G, Cuny C, Sharp T, Smith W, Petteway J, Brawer MK, et al: Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray-zone of total prostate-specific antigen. Urology 46: 187-194, 1995.
16. Prestigiacomo AF, Lilja H, Pettersson K, Wolfert RL, and Stamey TA: A comparison of the "free" fraction of serum prostate specific antigen (PSA) in men with benign and cancerous prostates. J Urol (in press).
17. Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Piironen T, Abrahamsson PA, Stenman UH, Dowell B, Lövgren T, and Lilja H: Free, complexed, and total serum PSA: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 154: 1090-1095, 1995.
18. Bangma CH, Kranse R, Blijenberg BG, and Schröder FH: The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density. Urology 46: 779-784, 1995.
19. Aus G, Bergdahl S, Fernlund P, Prosing R, Lilja H, Lodding P, and Hugosson J: Randomized study of screening of the prostate: results of PSA related screening in Göteborg, Sweden (abstract). Eur Urol 30(suppl 2): 549, 1996.